Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Frontiers in Immunology, 2018 Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj +1 more source
Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella [PDF]
, 2017 Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we ...
Berguer, Paula Mercedes +11 more
core +3 more sources
Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
Frontiers in Immunology, 2022 Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues ...
Alejandro Ramírez-Chacón +13 more
doaj +1 more source
Unlocking the potential of Tregs: innovations in CAR technology
Frontiers in Molecular Biosciences, 2023 Regulatory T cells (Tregs) adoptive immunotherapy is emerging as a viable treatment option for both autoimmune and alloimmune diseases. However, numerous challenges remain, including limitations related to cell number, availability of target-specific ...
Christopher J. Requejo Cier +2 more
doaj +1 more source
The case for absolute ligand discrimination : modeling information processing and decision by immune T cells [PDF]
, 2015 Some cells have to take decision based on the quality of surroundings ligands, almost irrespective of their quantity, a problem we name "absolute discrimination". An example of absolute discrimination is recognition of not-self by immune T Cells. We show
Altan-Bonnet, Grégoire, François, Paul
core +2 more sources
Tumor Biology, 2017 Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu +9 more
doaj +1 more source
Chimeric antigen receptor T-cell therapy.
Australian prescriber, 2023 Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale +2 more
openaire +2 more sources
Haematologica, 2016 Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent +13 more
doaj +1 more source
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Frontiers in Genetics, 2020 The term cancer stem cell (CSC) starts 25 years ago with the evidence that CSC is a subpopulation of tumor cells that have renewal ability and can differentiate into several distinct linages.
Rowa Y. Alhabbab
doaj +1 more source
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]
, 2018 Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P +10 more
core +1 more source